JPY 604.0
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 656.68 Million JPY | 26.59% |
2022 | 518.73 Million JPY | -10.89% |
2021 | 582.15 Million JPY | 60.35% |
2020 | 363.04 Million JPY | 12.44% |
2019 | 322.88 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 FY | 656.68 Million JPY | 26.59% |
2023 Q4 | 656.68 Million JPY | 16.26% |
2023 Q3 | 564.84 Million JPY | 30.79% |
2023 Q2 | 431.87 Million JPY | -4.51% |
2023 Q1 | 452.26 Million JPY | -12.81% |
2022 Q4 | 518.73 Million JPY | -4.03% |
2022 Q3 | 540.53 Million JPY | 24.09% |
2022 Q2 | 435.6 Million JPY | 0.06% |
2022 Q1 | 435.35 Million JPY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Shin Nippon Biomedical Laboratories, Ltd. | 42.14 Billion JPY | 98.442% |
DNA Chip Research Inc. | 250.12 Million JPY | -162.546% |
Cosmo Bio Company,Limited | 1.84 Billion JPY | 64.446% |
H.U. Group Holdings, Inc. | 152.84 Billion JPY | 99.57% |
FALCO HOLDINGS Co., Ltd. | 10.39 Billion JPY | 93.683% |
BML, Inc. | 40.85 Billion JPY | 98.392% |
Precision System Science Co., Ltd. | 2.25 Billion JPY | 70.862% |